National Jewish Medical And Research Center Receives $9 Million Grant To From NIH To Study Fibrotic Lung Disease

July 17, 1997

The National Heart, Lung and Blood Institute at the National Institutes of Health have awarded National Jewish Medical and Research Center a $9 million Specialized Center of Research grant to study the pathogenesis and treatment of pulmonary fibrosis.

The grant is $1.8 million a year for 5 years. This work will be part of the clinical and research program of the Pulmonary and Critical Care Division of the University of Colorado Health Sciences Center.

"We need to learn more about the basic mechanisms of fibrosis," said Robert Mason, M.D., a National Jewish physician and principal investigator of the study. "We're focusing on inflammation and growth factors as regulators of the fibrotic response."

People with pulmonary fibrosis, also known as interstitial lung disease, generally suffer from cough. Scarring in the lungs, caused by the disease, makes the lungs stiff and causes shortness of breath. "We're trying to prevent continued scar formation in the lungs," Dr. Mason said. "Pulmonary fibrosis is a devastating disease, like cancer, with a high mortality rate."

National Jewish will continue its basic studies on the mechanism of pulmonary fibrosis and initiate clinical trials aimed at limiting the fibrotic response. Kevin Brown, M.D., of National Jewish, will head the clinical patient assessment and be responsible for controlled clinical trials. This work will be performed in collaboration with physicians and investigators at the University of Colorado.

National Jewish researchers are conducting four interstitial lung disease research projects.

The research projects include:

  • The role of T cells in inducing pulmonary fibrosis
  • Interactions between the epithelium and the mesenchyme--a network of cells--during lung injury and treatment
  • Regulation of the paroduction of fibrogenic growth factors by macrophages
  • A clinical trial using interferon gamma to control inflammation in the lungs and to control the fibrotic response
    -end-


    National Jewish Health

    Related Pulmonary Fibrosis Articles from Brightsurf:

    The CNIO pave the way for a future gene therapy to reverse pulmonary fibrosis associated with ageing
    ''Our results indicate that a new therapy may be developed to prevent the development of pulmonary fibrosis associated with ageing,'' says CNIO's Maria Blasco, principal investigator of the study * Lung tissue of patients with pulmonary fibrosis does not regenerate because the cells involved in lung generation have damaged telomeres, the ends of the chromosomes.

    Pulmonary fibrosis treatment shows proof of principle
    A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

    Pulmonary embolism and COVID-19
    Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients.

    Stem cells from placental amniotic membrane slow lung scarring in pulmonary fibrosis
    In a study released today in STEM CELLS Translational Medicine (SCTM), researchers show for the first time how stem cells collected from human amniotic membrane can slow the progression of scarring in pulmonary fibrosis.

    Researchers identify key mechanisms involved in pulmonary fibrosis development
    Working alongside research groups from Heidelberg, researchers from Charité - Universitätsmedizin Berlin have elucidated the novel disease processes involved in the development of pulmonary fibrosis.

    Bacterial protein fragment kills lung cells in pulmonary fibrosis, study finds
    A bacterial protein fragment instigates lung tissue death in pulmonary fibrosis, a mysterious disease affecting millions of people worldwide, according to a new study from researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan.

    Closing in on liver fibrosis: Detailing the fibrosis process at unprecedented resolution
    Today, there is no effective way to treat liver fibrosis.

    Inhalation therapy shows promise against pulmonary fibrosis in mice, rats
    A new study shows that lung stem cell secretions -- specifically exosomes and secretomes -- delivered via nebulizer, can help repair lung injuries due to multiple types of pulmonary fibrosis in mice and rats.

    Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
    A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

    Short or long sleep associated with Pulmonary Fibrosis
    Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

    Read More: Pulmonary Fibrosis News and Pulmonary Fibrosis Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.